(@shrutipatelmd.bsky.social)

1/ 🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou @cancerassassin1.bsky.social, presented at #AACR24 thelancet.com/journals/lan... #oncology #crc Key findings from this landmark phase 1 trial 🧵:

loading . . .

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial These results support the safety and potential antitumour activity of inhibiting the immune checkpoint CISH through the administration of neoantigen-reactive CISH-knockout TILs, with implications for ... https://thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00083-X/abstract